rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guardant Health at Jefferies Global Healthcare Conference: growth broadens
      11h agoInvesting.comGH
      Guardant Health director Tariq Musa sells $17,348 in company stock
      20h agoInvesting.comGH
      Guardant Health director Alex Azar II sells $10,319 in shares
      Nov 18Investing.comGH
      Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 13Yahoo FinanceGH
      Why is Guardant Health stock climbing today?
      Nov 12Investing.comGH
      Guardant Health prices $500 million convertible notes offering
      Nov 12Investing.comGH
      Guardant Health Prices $500 Million Convertible Senior Notes Offering
      Nov 12Yahoo FinanceGH
      Guardant Health director Steve Krognes sells $1.17M in shares
      Nov 11Investing.comGH
      Guardant Health CTO Darya Chudova sells shares worth $1.38 million
      Nov 11Investing.comGH
      Guardant Health director Tariq Musa sells $20,300 in stock
      Nov 11Investing.comGH
      Guardant Health director Alex Azar II sells $144,550 in stock
      Nov 11Investing.comGH
      Guardant Health plans $500 million convertible notes offering
      Nov 11Investing.comGH
      Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
      Nov 11Yahoo FinanceGH
      GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability
      Nov 9Yahoo FinanceGH
      This cancer-testing stock is BTIG’s top pick after another major earnings beat
      Nov 9Yahoo FinanceGH
      Guardant Health (GH) Now Has A Harder Patent Fight After 23 Claims Survived
      Nov 7Yahoo FinanceGH
      Guardant Health Stocks Fall 9.49% as Cash Burn Outlook Rises Despite 36% Growth

      Shield screening volume more than tripled, but Guardant now expects $205 million to $220 million of 2026 cash burn.

      Nov 6Yahoo FinanceGH
      Guardant Health, Inc. Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceGH
      Guardant Health stock reiterated at Buy by BTIG after Q3 beat
      Nov 6Investing.comGH
      Guardant Health Shares Fall 5.5% as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth
      Nov 6Yahoo FinanceGH
      Why is Guardant Health stock sliding today?
      Nov 6Investing.comGH
      Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36% as Shield ...

      Guardant Health Inc (GH) posted $361 million in Q3 2026 revenue, driven by explosive Shield adoption and oncology volume growth, while raising full-year guidance to $1.36-$1.37 billion.

      Nov 6Yahoo FinanceGH
      What Guardant Health (GH) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceGH
      Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

      Guardant Health (GH) delivered earnings and revenue surprises of 0.00% and +2.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 6Yahoo FinanceGH
      Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
      Nov 5Yahoo FinanceGH
      Guardant Health falls 12% as cash burn guidance disappoints
      Nov 5Investing.comGH
      Guardant Health: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceGH
      Guardant Health Q3 2026 Earnings Call Transcript
      Nov 5BenzingaGH
      Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%
      Nov 5Yahoo FinanceGH
      Blood-Testing Gore Continues As Natera, Guardant Report

      Shares of both plummeted following their third-quarter reports.

      Nov 5Investor's Business DailyGHNTRA
      Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
      Nov 5Yahoo FinanceGH
      Guardant Health (GH) Could Be 17% Undervalued As Board Appointment Tests Valuation

      Guardant Health (GH) has drawn fresh attention after appointing Kevin Sayer, former Dexcom CEO and current Executive Chairman, to its board of directors. The move is raising new questions about where the stock’s story goes next. Guardant Health’s share price has pulled back in the short term, with a 1-day share price return of down 3.67% and a 7-day share price return of down 9.03%, even as the year-to-date share price return of 65.70% and a 1-year total shareholder return of 75.15% point to...

      Nov 5Yahoo FinanceGH
      Will Shield Award Recognition Change Guardant Health Stock Narrative

      Guardant Health reported that its Shield blood test for colorectal cancer screening received the 2026 Prix Galien USA Award for Best Medical Technology, recognizing the first FDA approved blood test for primary colorectal cancer screening and its role in raising screening participation and adherence in real world use. The company also added Kevin Sayer, former Dexcom CEO and current Executive Chairman, to its board. This brings deep digital health operating experience and governance insight...

      Nov 5Yahoo FinanceGH
      Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics
      Nov 4Yahoo FinanceGH
      Kevin Sayer Joins Guardant Health Board of Directors
      Nov 3Yahoo FinanceDXCMGH
      Guardant Health board approves performance-based stock grants for co-CEOs
      Nov 3Investing.comGH
      Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
      Nov 3Yahoo FinanceGH
      Guardant Health options signal 14% stock move on earnings
      Oct 29Investing.comGH
      Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

      Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 29Yahoo FinanceGH
      Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
      Oct 29Yahoo FinanceGH
      BTIG raises Guardant Health stock price target on growth outlook
      Oct 27Investing.comGH
      This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
      Oct 23BenzingaGH
      Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
      Oct 23Yahoo FinanceGHNTRADECKGLHESMKMBTMO
      Roth Capital Initiates Coverage on Guardant Health With Buy Rating, $200 Price Target
      Oct 23Yahoo FinanceGH
      The Stock Of The Day, And Its Rivals, Are Taking A Breather

      Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.

      Oct 22Investor's Business DailyGHNEONTRA
      Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Alvotech (ALVO)

      Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailALVOALVOWGH
      Natera Partners With TransCode to Advance Colorectal Cancer Trial
      Oct 21Yahoo FinanceGHNTRA
      Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?
      Oct 20Yahoo FinanceGH
      Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

      PALO ALTO, Calif., October 20, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad

      Oct 20Yahoo FinanceGH
      Guardant Health director Tariq Musa sells $19,242 in stock
      Oct 20Investing.comGH

      This is the newest page. Registered accounts read further back.